Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model

Ji,Xiang-Jun; Chen,Sui-Hua; Zhu,Lin; Pan,Hao; Zhou,Yuan; Li,Wei; You,Wan-Chun; Gao,Chao-Chao; Zhu,Jian-Hong; Jiang,Kuan; Wang,Han-Dong

doi:10.3892/or.2013.2476

Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model

Authors:
- Xiang-Jun Ji
- Sui-Hua Chen
- Lin Zhu
- Hao Pan
- Yuan Zhou
- Wei Li
- Wan-Chun You
- Chao-Chao Gao
- Jian-Hong Zhu
- Kuan Jiang
- Han-Dong Wang
View Affiliations

Affiliations: Department of Neurosurgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China, Department of Ophthalmology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China
Published online on: May 15, 2013 https://doi.org/10.3892/or.2013.2476
Pages: 157-164

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NF-E2-related factor 2 (Nrf2) is a pivotal transcription factor of cellular responses to oxidative stress and recent evidence suggests that Nrf2 plays an important role in cancer pathobiology. However, the underlying mechanism has yet to be elucidated, particularly in glioma. In the present study, we investigated the role of Nrf2 in the clinical prognosis, cell proliferation and tumor growth of human glioblastoma multiforme (GBM). We detected overexpression of Nrf2 protein levels in GBM compared to normal brain tissues. Notably, higher protein levels of Nrf2 were significantly associated with poorer overall survival and 1-year survival for GBM patients. Furthermore, we constructed the plasmid Si-Nrf2 and transduced it into U251MG cells to downregulate the expression of Nrf2 and established stable Nrf2 knockdown cells. The downregulation of Nrf2 suppressed cell proliferation in vitro and tumor growth in mouse xenograft models. We performed immunohistochemistry staining to detect the protein levels of Nrf2, Ki-67, caspase-3 and CD31 in the xenograft tumors and found that the expression levels of Nrf2 and Ki-67 were much lower in the Si-Nrf2 group compared to the Si-control group. In addition, the number of caspase-3-positive cells was significantly increased in the Si-Nrf2 group. By analysis of microvessel density (MVD) assessed by CD31, the MVD value in the Si-Nrf2 group decreased significantly compared to the Si-control group. These findings indicate that the knockdown of Nrf2 may suppress tumor growth by inhibiting cell proliferation, increasing cell apoptosis and inhibiting angiogenesis. These results highlight the potential of Nrf2 as a candidate molecular target to control GBM cell proliferation and tumor growth.

View Figures

View References

1	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
2	Sullivan PR: Brain tumors. N Engl J Med. 344:1478author reply 1479. 2001. View Article : Google Scholar : PubMed/NCBI
3	Chen J, McKay RM and Parada LF: Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 149:36–47. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res. 58:262–270. 2008. View Article : Google Scholar : PubMed/NCBI
5	Dinkova-Kostova AT, Liby KT, Stephenson KK, et al: Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA. 102:4584–4589. 2005. View Article : Google Scholar
6	Kwak MK, Itoh K, Yamamoto M, Sutter TR and Kensler TW: Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med. 7:135–145. 2001.PubMed/NCBI
7	Shih AY, Li P and Murphy TH: A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci. 25:10321–10335. 2005. View Article : Google Scholar
8	Yan W, Wang HD, Feng XM, Ding YS, Jin W and Tang K: The expression of NF-E2-related factor 2 in the rat brain after traumatic brain injury. J Trauma. 66:1431–1435. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Fields J, Zhao C, et al: Role of Nrf2 in protection against intracerebral hemorrhage injury in mice. Free Radic Biol Med. 43:408–414. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hayes JD and McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
11	Hayes JD and McMahon M: The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell. 21:732–734. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kensler TW and Wakabayashi N: Nrf2: friend or foe for chemoprevention? Carcinogenesis. 31:90–99. 2010. View Article : Google Scholar : PubMed/NCBI
13	Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yamadori T, Ishii Y, Homma S, et al: Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene. 45:4768–4777. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lister A, Nedjadi T, Kitteringham NR, et al: Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 10:372011. View Article : Google Scholar : PubMed/NCBI
16	Kim TH, Hur EG, Kang SJ, et al: NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res. 71:2260–2275. 2011.PubMed/NCBI
17	Pan H, Wang H, Zhu L, Mao L, Qiao L and Su X: The role of Nrf2 in migration and invasion of human glioma cell U251. World Neurosurg. Nov 7–2011.(Epub ahead of print).
18	Rousseau A, Mokhtari K and Duyckaerts C: The 2007 WHO classification of tumors of the central nervous system - what has changed? Curr Opin Neurol. 21:720–727. 2008. View Article : Google Scholar : PubMed/NCBI
19	Bustin SA, Benes V, Garson JA, et al: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hu Z, Lin D, Yuan J, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 11:4646–4652. 2005. View Article : Google Scholar : PubMed/NCBI
21	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
22	Wang M, Tang J, Liu S, Yoshida D and Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol. 71:3–7. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
24	Moi P, Chan K, Asunis I, Cao A and Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar
25	Padmanabhan B, Tong KI, Ohta T, et al: Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell. 21:689–700. 2006. View Article : Google Scholar : PubMed/NCBI
26	Singh A, Misra V, Thimmulappa RK, et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3:e4202006. View Article : Google Scholar
27	Shibata T, Kokubu A, Gotoh M, et al: Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 135:1358–1368. 2008. View Article : Google Scholar : PubMed/NCBI
28	Nioi P and Nguyen T: A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun. 362:816–821. 2007. View Article : Google Scholar : PubMed/NCBI
29	Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
30	Konstantinopoulos PA, Spentzos D, Fountzilas E, et al: Keap1 mutations and nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 71:5081–5089. 2011. View Article : Google Scholar : PubMed/NCBI
31	Merikallio H, Paakko P, Kinnula VL, Harju T and Soini Y: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol. 43:577–584. 2011. View Article : Google Scholar : PubMed/NCBI
32	Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
33	Wiesner FG, Magener A, Fasching PA, et al: Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast. 18:135–141. 2009. View Article : Google Scholar : PubMed/NCBI
34	Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
35	Niture SK and Jaiswal AK: Nrf2 up-regulates anti-apoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI
36	Choi YK, Kim CK, Lee H, et al: Carbon monoxide promotes VEGF expression by increasing HIF-1α protein level via two distinct mechanisms, translational activation and stabilization of HIF-1α protein. J Biol Chem. 285:32116–32125. 2010.PubMed/NCBI